جميع الدراسات
التوظيفرَصْدِيّ

PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]

This study, called PRECISE PASS, is looking into a medicine called Xromi (hydroxycarbamide oral solution) for babies and toddlers aged 9 months to just under 2 years old who have sickle cell disease. Its main goal is to check how safe Xromi is and how well it helps control the condition in real-life situations. Researchers will follow a group of children who are given Xromi and compare them to a similar group of children who haven't taken this medicine. They will be observed for 24 months. By comparing these groups, doctors hope to learn more about the benefits and any possible side effects of Xromi for these very young patients, using information from their regular doctor visits.

نظرة سريعة

الحالة
التوظيف
الراعي
Nova Laboratories Limited
الهدف من التسجيل
180
ابدأ
09 يونيو 2025
التاريخ المتوقع للانتهاء
01 Jun 2029

ما هو موضوع هذه الدراسة؟

Sickle cell disease is a lifelong condition that affects red blood cells. It can cause a lot of pain and other serious problems. Xromi is a medicine designed to help manage sickle cell disease and reduce these complications. This particular study, called PRECISE PASS, is focusing on very young children, specifically those aged 9 months up to their second birthday.

The main purpose of this study is to carefully watch children taking Xromi and see how safe it is for them, as well as how well it works in everyday medical care. They want to understand if there are any side effects and if it genuinely helps children with sickle cell disease. The study will look at children already prescribed Xromi and compare them to children who have not received this treatment. This comparison helps researchers understand Xromi's effects better.

Researchers will follow these children for two years (24 months), collecting information from their regular visits to the doctor. It's important to know that this isn't a study where new treatments are tested. Instead, it observes how Xromi is used in usual medical practice. The study aims to provide important information to doctors and families about using Xromi safely and effectively in very young children with sickle cell disease.

النقاط الرئيسية

  • Study examines Xromi's safety and effectiveness in children under 2 with sickle cell disease.
  • Compares children taking Xromi to those not taking it, using routine medical data.
  • Children are followed for 24 months (two years).
  • No extra treatments or appointments are needed for the study.
  • Aims to improve understanding of Xromi for this young age group.
  • المشاركة طوعية ويمكن سحبها في أي وقت.

من قد يكون مؤهلاً؟

To be considered for the group taking Xromi, your child must be between 9 months and just under 2 years old, have sickle cell disease, and have been prescribed Xromi to help manage their condition. It's also important that they haven't taken any form of hydroxycarbamide before and aren't getting regular blood transfusions every 8 weeks or more often. Your child also shouldn't have specific serious liver or kidney problems, very low blood cell counts, other active serious illnesses, or be on certain other medications like those for HIV. You, as the parent or legal guardian, would need to give your permission for your child to be part of the study.

For the comparison group, children need to be between 9 months and just under 2 years old with sickle cell disease and haven't had Xromi or similar medicines. These children will be chosen to closely match the children taking Xromi in terms of age and their specific type of sickle cell disease. Again, parent or guardian permission is needed.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. Is your child between 9 months and just under 2 years old?
  2. Does your child have sickle cell disease?
  3. Has your child been prescribed Xromi, or have they never taken similar medication?
  4. Has your child received regular blood transfusions every 8 weeks or more often?
  5. Does your child have specific serious liver/kidney problems, very low blood counts, or other serious health issues?
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If your child takes part, they will either be in the group already prescribed Xromi or a comparison group that hasn't taken it. No new treatments or extra tests will be given specifically for this study. The researchers will simply collect information from your child's regular medical notes and clinic visits over a period of 24 months, starting from when they began Xromi or a similar 'start date' for the comparison group. You won't need to attend any extra appointments or do anything special just for the study; all information comes from your child's usual care. The study is planned to take place in specialised hospitals in the UK and Germany, and possibly other European countries.

المخاطر والفوائد المحتملة

Being part of this study helps doctors learn more about how Xromi works in young children, which could benefit others with sickle cell disease in the future. As this study collects information from routine care, there are no additional medical risks from participation beyond what is already involved in your child's standard treatment for sickle cell disease. You or your child's doctor can decide to withdraw your child from the study at any time, without it affecting their medical care.

المواقع (12)

  • Universitätsklinikum Hamburg-Eppendorf
    الرمز البريدي المؤكد
    هامبورغ، ألمانيا· التوظيف
  • Universitätsklinikum Heidelberg
    الرمز البريدي المؤكد
    هايدلبرغ، ألمانيا· التوظيف
  • Basildon University Hospital
    الرمز البريدي المؤكد
    باسيلدون، المملكة المتحدة· التوظيف
  • Noah's Ark Children's Hospital for Wales
    الرمز البريدي المؤكد
    كارديف، المملكة المتحدة· التوظيف
  • Evelina London Children's Hospital
    الرمز البريدي المؤكد
    لندن، المملكة المتحدة· التوظيف
  • Kings College Hospital
    الرمز البريدي المؤكد
    لندن، المملكة المتحدة· التوظيف
  • North Middlesex University Hospital
    الرمز البريدي المؤكد
    لندن، المملكة المتحدة· التوظيف
  • The Royal London Hospital
    الرمز البريدي المؤكد
    لندن، المملكة المتحدة· التوظيف
  • مستشفى كلية جامعة لندن
    الرمز البريدي المؤكد
    لندن، المملكة المتحدة· التوظيف
  • Whittington Hospital
    الرمز البريدي المؤكد
    لندن، المملكة المتحدة· التوظيف
  • مستشفى رويال مانشستر للأطفال
    الرمز البريدي المؤكد
    مانشستر، المملكة المتحدة· التوظيف
  • John Radcliffe Hospital
    الرمز البريدي المؤكد
    أوكسفورد، المملكة المتحدة· التوظيف

أسئلة شائعة

What is Xromi?

Xromi is a liquid medicine that contains hydroxycarbamide, used to treat sickle cell disease.

Is this a new medicine being tested?

No, Xromi is already available. This study is observing how it works in real-life settings for very young children.

كم من الوقت سيبقى طفلي في الدراسة؟

Your child will be followed for 24 months (two years) from when they start Xromi or a similar 'start date' for children not taking it.

Will my child need extra doctor visits?

No, all information for the study will come from your child's regular doctor appointments and medical records.

Can I remove my child from the study?

Yes, you can decide to withdraw your child from the study at any time, and it won't affect their medical care.

كيفية معرفة المزيد

Hussain Mulla, PhD

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

هل أنت مهتم بالمشاركة؟

سجل اهتمامك

شارك تفاصيلك وفريق البحث لـ "PASS of Xromi Comparing Safety and Effectiveness in Children… "سيتواصل معك إذا كنت مؤهلاً. تحدث دائمًا إلى طبيبك قبل الموافقة على المشاركة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.